The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity

Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?

“…[10] Conversely, endoscopic intragastric balloon (IGB) insertion is a noninvasive method that produces weight reduction in up to 35% of patients according to randomized controlled trials. [1112] Liraglutide (Victoza ® , Novo Nordisk, Bagsvaerd, Denmark), a parenteral glucagon-like peptide type 1 (GLP-1) agonist used to treat DM-2 that has a weight reducing effect, was approved by the food and drug administration (FDA) in 2013 for the treatment of DM-2 and in 2014 for weight reduction (www.fda.gov). Liraglutide is considered an expensive medication with an average monthly cost of 500$ for those without medical insurance.…”

Gastrointestinal devices for the treatment of type 2 diabetes

“…Modern saline-filled intragastric balloons have been used outside the United States (U.S.) since 1997 with reported percent excess weight loss (%EWL) ranging from 25 to 40%. 7 One recent iteration of this concept is the Orbera BioEnterics Intragastric Balloon TM ( Allergan BioEnterics Corporation, Irvine, USA) (Fig. 1) .…”

“…7 The devices were removed at 24 weeks, and the patients were followed for 48 weeks. This study found that there was a significantly greater weight loss in the balloon therapy group at 24 weeks with mean %EWL of 25.1% vs. 11.3% in the sham group.…”

Update on bariatric surgical procedures and an introduction to the implantable weight loss device: the Maestro Rechargeable System

“…The balloons are endoscopically placed into the stomach and filled with saline, intending to occupy space in the stomach to induce satiety and decrease food intake (Figure 6). Studies have shown the balloons to induce %EWL of 25%–40% 31. Side effects and complications include nausea, vomiting, abdominal pain, ulcer development, balloon deflation, and device migration.…”